NetworkNewsBreaks – AzurRx BioPharma Inc. (NASDA
Post# of 66
(Total Views: 323)
Posted On: 10/14/2020 3:45:00 PM
NetworkNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Adds More Sites for Cystic Fibrosis Clinical Trials
AzurRx BioPharma (NASDAQ: AZRX) has activated additional clinical trial sites for its trial of MS1819 in cystic fibrosis. The company specializes in the development of nonsystemic, recombinant therapies for gastrointestinal diseases. The company has activated two additional trial sites in Turkey for its Phase 2 combination therapy trial of its lead drug candidate, MS1819. MS1819 is a recombinant lipase for the treatment of exocrine pancreatic insufficiency (“EPI”) in patients suffering from chronic pancreatitis and cystic fibrosis. Patient screening has already been initiated for the new trial sites, with topline data expected by Q2 2021. AzurRx had previously activated six clinical sites in Hungary, where dosing of patients has already begun. This new announcement makes a total of eight identified sites; the company ultimately plans on having twelve European sites active for these clinical trials. “We are truly pleased and encouraged by the interest in our expanding global Phase 2 Combination Trial,” said AzurRx chief medical officer James Pennington, MD, in the press release. “The recently reported interim data suggests promising results and the full data readout is expected in the second quarter of next year. Our investigators in Turkey have been extremely diligent in driving the start-up of this trial in a very efficient and effective manner, and we look forward to our continued work with them.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
AzurRx BioPharma (NASDAQ: AZRX) has activated additional clinical trial sites for its trial of MS1819 in cystic fibrosis. The company specializes in the development of nonsystemic, recombinant therapies for gastrointestinal diseases. The company has activated two additional trial sites in Turkey for its Phase 2 combination therapy trial of its lead drug candidate, MS1819. MS1819 is a recombinant lipase for the treatment of exocrine pancreatic insufficiency (“EPI”) in patients suffering from chronic pancreatitis and cystic fibrosis. Patient screening has already been initiated for the new trial sites, with topline data expected by Q2 2021. AzurRx had previously activated six clinical sites in Hungary, where dosing of patients has already begun. This new announcement makes a total of eight identified sites; the company ultimately plans on having twelve European sites active for these clinical trials. “We are truly pleased and encouraged by the interest in our expanding global Phase 2 Combination Trial,” said AzurRx chief medical officer James Pennington, MD, in the press release. “The recently reported interim data suggests promising results and the full data readout is expected in the second quarter of next year. Our investigators in Turkey have been extremely diligent in driving the start-up of this trial in a very efficient and effective manner, and we look forward to our continued work with them.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)